Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
Angiotensin‐converting enzyme inhibitors may leads to higher adverse events: number reporting an adverse event compared with placebo (low certainty).
1 finding from 1 review
Kidney failure progression: doubling of SCr (mg/dL) · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Cardiovascular events · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with early (stage 1 to 3) non‐diabetic CKD
It is very uncertain whether angiotensin receptor blockers changes adverse events (number reporting an adverse event) compared with placebo (very low certainty).
1 finding from 1 review
Kidney failure progression: eGFR (mL/min/1.73m²) · adults with early (stage 1 to 3) non‐diabetic CKD
1 finding from 1 review
Death (any cause) · adults with early (stage 1 to 3) non‐diabetic CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease-free survival · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
Participants requiring chemotherapy delays · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher participants requiring chemotherapy delays compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Participants requiring dose reduction · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · early triple‐negative breast cancer
1 finding from 1 review
Quality of life · early triple‐negative breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
OS at 2 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to higher pathological complete response compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
Disease-free survival · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower DFS at 2 years compared with chemotherapy without platinum (high certainty).
2 findings from 1 review
OS at 2 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review
OS at 5 years · early triple‐negative breast cancer
Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).
1 finding from 1 review